BAC water • component-specific concentration • clinical evidence

How Much BAC Water for CagriSema? Research Reconstitution & Concentration Guide

CagriSema is an investigational combination of cagrilintide + semaglutide. For a hypothetical lyophilized research material containing both components, the BAC-water volume determines the final concentration of each active component. Because CagriSema contains two actives, the most useful research calculation is to track cagrilintide concentration and semaglutide concentration separately.

INVESTIGATIONAL PHASE 3 EVIDENCE RESEARCH CONCENTRATION
Current U.S. status: CagriSema is not FDA approved as of September 13, 2026. Novo Nordisk has submitted CagriSema for U.S. review in obesity, with a regulatory decision expected in Q4 2026.

Recommended CagriSema Research Concentration Formulas

There is no universal BAC-water volume for every CagriSema research material. The appropriate research calculation depends on the stated quantity of each component in the vial and the target laboratory concentration.

Cagrilintide concentration (mg/mL) = cagrilintide quantity (mg) ÷ final liquid volume (mL) Semaglutide concentration (mg/mL) = semaglutide quantity (mg) ÷ final liquid volume (mL) Required final liquid volume (mL) = component quantity (mg) ÷ target component concentration (mg/mL)

Quick Reference: Equal-Ratio CagriSema Research Materials

CagriSema clinical development has prominently used equal cagrilintide-to-semaglutide ratios. The table below therefore demonstrates equal-ratio mathematical examples. It does not establish a preparation method for any commercial, investigational, or research product.

Hypothetical research vial Final liquid volume Cagrilintide concentration Semaglutide concentration Total combined concentration
2.5 mg cagrilintide + 2.5 mg semaglutide 1 mL 2.5 mg/mL 2.5 mg/mL 5 mg/mL total
2.5 mg + 2.5 mg 2 mL 1.25 mg/mL 1.25 mg/mL 2.5 mg/mL total
5 mg + 5 mg 2 mL 2.5 mg/mL 2.5 mg/mL 5 mg/mL total
5 mg + 5 mg 4 mL 1.25 mg/mL 1.25 mg/mL 2.5 mg/mL total
10 mg + 10 mg 4 mL 2.5 mg/mL 2.5 mg/mL 5 mg/mL total
10 mg + 10 mg 8 mL 1.25 mg/mL 1.25 mg/mL 2.5 mg/mL total
Why BacScience does not state one universal “best” BAC-water volume: a research material sold under the CagriSema name can differ in component ratio, total quantity, excipients, purity, vial capacity, stability and validated laboratory protocol. Concentration arithmetic alone does not establish solubility, compatibility, sterility or suitability for any biological application.
Do not derive research-vial preparation from clinical trial doses. Published CagriSema trials describe investigational clinical formulations and study regimens. A clinical quantity such as 2.4 mg + 2.4 mg does not establish how an unrelated research vial should be reconstituted.

CagriSema BAC Water Calculator

Use the BacScience calculator for mathematical concentration work, then calculate each component separately.

Open BAC Water Calculator

How Much BAC Water for Common CagriSema Research Vial Configurations?

2.5 mg + 2.5 mg Equal-Ratio Research Material

Final liquid volume Cagrilintide Semaglutide Total combined
1 mL 2.5 mg/mL 2.5 mg/mL 5 mg/mL
2 mL 1.25 mg/mL 1.25 mg/mL 2.5 mg/mL
2.5 mL 1 mg/mL 1 mg/mL 2 mg/mL
5 mL 0.5 mg/mL 0.5 mg/mL 1 mg/mL

5 mg + 5 mg Equal-Ratio Research Material

Final liquid volume Cagrilintide Semaglutide Total combined
1 mL 5 mg/mL 5 mg/mL 10 mg/mL
2 mL 2.5 mg/mL 2.5 mg/mL 5 mg/mL
4 mL 1.25 mg/mL 1.25 mg/mL 2.5 mg/mL
5 mL 1 mg/mL 1 mg/mL 2 mg/mL

10 mg + 10 mg Equal-Ratio Research Material

Final liquid volume Cagrilintide Semaglutide Total combined
2 mL 5 mg/mL 5 mg/mL 10 mg/mL
4 mL 2.5 mg/mL 2.5 mg/mL 5 mg/mL
8 mL 1.25 mg/mL 1.25 mg/mL 2.5 mg/mL
10 mL 1 mg/mL 1 mg/mL 2 mg/mL
Component-specific calculation matters: If the stated cagrilintide-to-semaglutide ratio is not 1:1, calculate each component independently using its own milligram quantity divided by the same final liquid volume.

These are concentration-math examples only. No syringe-unit conversions, human dosing calculations, injection volumes or administration instructions are provided.

Clinical Research Snapshot

CombinationCagrilintide + semaglutide
MechanismsAmylin-pathway agonism + GLP-1 receptor agonism
U.S. statusInvestigational; FDA review underway in obesity
Clinical phasePhase 3 / Phase 3a development
Major populationsOverweight or obesity, with and without type 2 diabetes
Current review timingU.S. decision expected Q4 2026 according to Novo Nordisk

What Is CagriSema?

CagriSema is the investigational combination of cagrilintide and semaglutide. Cagrilintide is a long-acting amylin analogue; semaglutide is a GLP-1 receptor agonist.

The combination has been developed to investigate whether complementary amylin and GLP-1 pathways can produce additive or synergistic metabolic effects.

CagriSema Components

Cagrilintide Long-acting amylin analogue involved in appetite, gastric and metabolic signaling research.
Semaglutide GLP-1 receptor agonist with established FDA-approved uses as a separate active ingredient in specific drug products.
Why this matters for BAC-water math: CagriSema should not be treated mathematically as one unidentified compound. When a research material provides quantities for both components, each component concentration should be calculated separately.

Mechanism of Action

Cagrilintide acts through amylin-related signaling, while semaglutide activates the GLP-1 receptor. These complementary pathways are associated with appetite, food intake, gastric physiology, glucose regulation and broader metabolic effects.

FDA / Regulatory Status

CagriSema is not FDA approved in the United States as of September 13, 2026.

Novo Nordisk reports that the U.S. CagriSema submission for obesity is under review and that a decision is expected in Q4 2026. Submission for marketing authorization is not the same as approval.

Semaglutide alone Separately FDA approved in specific products and indications.
CagriSema combination Investigational and under U.S. regulatory review.

Major CagriSema Clinical Trials

Trial Phase Population Investigational regimen Key research point Source
REDEFINE 1 3a Overweight or obesity without diabetes 2.4 mg cagrilintide + 2.4 mg semaglutide weekly Large global weight-management study with component comparator arms. PubMed
REDEFINE 2 3a Overweight or obesity with type 2 diabetes 2.4 mg + 2.4 mg weekly Evaluated body weight, glycemic outcomes and safety. PubMed
REDEFINE 5 3a Adults in Japan and Taiwan with overweight or obesity 2.4 mg + 2.4 mg weekly Published 2026 head-to-head evidence versus semaglutide. PubMed
REIMAGINE 1 3a Type 2 diabetes inadequately controlled with diet and exercise Once-weekly CagriSema regimens Published 2026 efficacy and safety study. PubMed
REIMAGINE 2 3 Type 2 diabetes with overweight or obesity 2.4/2.4 mg and 1.0/1.0 mg groups Compared CagriSema with semaglutide or cagrilintide. PubMed
REIMAGINE 3 3 Type 2 diabetes receiving basal insulin 2.4/2.4 mg and 1.0/1.0 mg groups Evaluated CagriSema as add-on to basal insulin. PubMed

Clinical-trial quantities above are reported for scientific context only and should not be converted into research-vial preparation or individual treatment instructions.

CagriSema Clinical Evidence Highlights

REDEFINE 1 Phase 3a

Large randomized obesity trial comparing CagriSema with semaglutide, cagrilintide and placebo.

REDEFINE 5 2026

Published evidence comparing cagrilintide-semaglutide with semaglutide in Japan and Taiwan.

REIMAGINE 2026

Multiple published phase 3 studies expanded the evidence base in type 2 diabetes.

The 2026 REIMAGINE publications strengthen the clinical evidence base for CagriSema in type 2 diabetes, while REDEFINE 5 adds phase 3a comparative data from Japan and Taiwan. These results support scientific evaluation of the combination but do not themselves establish FDA approval.

Adverse Events & Safety Findings

Gastrointestinal adverse events have been prominent across CagriSema clinical development, including nausea, vomiting, diarrhea and constipation. Because the combination remains investigational, safety continues to be characterized through ongoing trials and regulatory review.

Research Limitations & Reconstitution Boundaries

Combination attributionEffects cannot automatically be assigned to only cagrilintide or only semaglutide.
Research-vial variabilityComponent ratio, formulation and excipients may differ across materials.
Trial formulationClinical study presentations do not create a universal BAC-water rule.
Regulatory statusU.S. regulatory review is ongoing as of September 13, 2026.

CagriSema Reconstitution & Research FAQ

How much BAC water should be used for CagriSema research?

There is no universal BAC-water volume for every CagriSema research material. Calculate from the stated cagrilintide quantity, stated semaglutide quantity and the desired laboratory concentration. Each component should be calculated separately.

How do you calculate CagriSema concentration?

Divide the cagrilintide quantity by the final liquid volume to obtain cagrilintide mg/mL, and divide the semaglutide quantity by the same final liquid volume to obtain semaglutide mg/mL.

How much BAC water for a 2.5 mg + 2.5 mg CagriSema research material?

As pure concentration mathematics, 1 mL final volume yields 2.5 mg/mL of each component; 2 mL yields 1.25 mg/mL of each component; and 2.5 mL yields 1 mg/mL of each component.

How much BAC water for a 5 mg + 5 mg CagriSema research material?

Mathematically, 2 mL final volume yields 2.5 mg/mL cagrilintide and 2.5 mg/mL semaglutide; 4 mL yields 1.25 mg/mL of each component; and 5 mL yields 1 mg/mL of each component.

How much BAC water for a 10 mg + 10 mg CagriSema research material?

Mathematically, 4 mL final volume yields 2.5 mg/mL of each component; 8 mL yields 1.25 mg/mL of each component; and 10 mL yields 1 mg/mL of each component. Actual vial capacity must be verified.

What if the Cagrilintide-to-Semaglutide ratio is not 1:1?

Calculate each component independently. Divide each component's stated milligram quantity by the same final liquid volume. Do not assume equal concentrations when the quantities are different.

Is CagriSema FDA approved?

No. As of September 13, 2026, CagriSema remains investigational in the United States. Novo Nordisk reports a U.S. regulatory decision is expected in Q4 2026.

Is Semaglutide approval the same as CagriSema approval?

No. Semaglutide is separately FDA approved in specific drug products and indications. Those approvals do not establish approval of the cagrilintide + semaglutide combination.

What is CagriSema?

CagriSema is the investigational combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist.

Does this page provide human CagriSema dosing or injection instructions?

No. This page provides research concentration mathematics and scientific reference information only. It does not provide dosing, syringe-unit conversion, injection, compounding or treatment instructions.

Scientific & Regulatory References

  1. Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025. PubMed.
  2. Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025. PubMed.
  3. Yamauchi T, et al. REDEFINE 5: cagrilintide-semaglutide versus semaglutide in adults with overweight or obesity in Japan and Taiwan. Lancet Diabetes Endocrinol. 2026. PubMed.
  4. Aroda VR, et al. REIMAGINE 1: once-weekly cagrilintide-semaglutide in adults with type 2 diabetes. Lancet Diabetes Endocrinol. 2026. PubMed.
  5. Buse JB, et al. REIMAGINE 2: cagrilintide-semaglutide versus semaglutide or cagrilintide in people with type 2 diabetes. Lancet Diabetes Endocrinol. 2026. PubMed.
  6. Rosenstock J, et al. REIMAGINE 3: cagrilintide-semaglutide as an add-on to basal insulin in adults with type 2 diabetes. Lancet. 2026. PubMed.
  7. Novo Nordisk. Q2 2026 investor presentation — CagriSema development and U.S. regulatory timing. Novo Nordisk.
Last scientifically reviewed: September 13, 2026. This page is an educational scientific research reference. CagriSema remains investigational in the United States. It is not medical advice, an FDA-approved treatment protocol, a compounding guide, a human dosing guide, or a substitute for trial-specific documentation.